Bank Pictet & Cie Europe AG Has $1.33 Million Holdings in Johnson & Johnson (NYSE:JNJ)

Bank Pictet & Cie Europe AG trimmed its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 21.5% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 9,218 shares of the company's stock after selling 2,525 shares during the period. Bank Pictet & Cie Europe AG's holdings in Johnson & Johnson were worth $1,333,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Knuff & Co LLC grew its position in shares of Johnson & Johnson by 0.7% in the third quarter. Knuff & Co LLC now owns 9,466 shares of the company's stock valued at $1,534,000 after purchasing an additional 64 shares during the last quarter. Vertex Planning Partners LLC boosted its holdings in Johnson & Johnson by 1.3% in the 3rd quarter. Vertex Planning Partners LLC now owns 5,211 shares of the company's stock valued at $844,000 after purchasing an additional 65 shares during the period. Freedom Day Solutions LLC grew its position in shares of Johnson & Johnson by 1.1% during the 3rd quarter. Freedom Day Solutions LLC now owns 6,269 shares of the company's stock worth $1,016,000 after purchasing an additional 66 shares in the last quarter. Traphagen Investment Advisors LLC increased its holdings in shares of Johnson & Johnson by 0.6% during the third quarter. Traphagen Investment Advisors LLC now owns 10,483 shares of the company's stock worth $1,699,000 after purchasing an additional 67 shares during the period. Finally, Corepath Wealth Partners LLC raised its position in shares of Johnson & Johnson by 3.7% in the fourth quarter. Corepath Wealth Partners LLC now owns 1,985 shares of the company's stock valued at $287,000 after buying an additional 70 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company's stock.

Remove Ads

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on JNJ shares. Morgan Stanley reduced their price target on Johnson & Johnson from $175.00 to $163.00 and set an "equal weight" rating on the stock in a research report on Thursday, January 23rd. Bank of America dropped their price target on Johnson & Johnson from $160.00 to $159.00 and set a "neutral" rating for the company in a research note on Thursday, January 23rd. Argus upgraded shares of Johnson & Johnson to a "strong-buy" rating in a research note on Friday, January 24th. Guggenheim boosted their target price on shares of Johnson & Johnson from $162.00 to $166.00 and gave the company a "neutral" rating in a research report on Monday, February 3rd. Finally, Wolfe Research started coverage on shares of Johnson & Johnson in a report on Friday, November 15th. They set an "outperform" rating and a $190.00 price target for the company. Nine equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, Johnson & Johnson currently has an average rating of "Moderate Buy" and an average target price of $170.67.

Johnson & Johnson Price Performance

JNJ stock traded up $2.67 during midday trading on Friday, reaching $162.35. 12,540,171 shares of the stock were exchanged, compared to its average volume of 9,073,381. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86. The stock has a market capitalization of $390.87 billion, a PE ratio of 24.41, a P/E/G ratio of 2.53 and a beta of 0.52. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $168.85. The company has a fifty day moving average price of $148.93 and a 200 day moving average price of $155.90.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, topping the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The company had revenue of $22.52 billion for the quarter, compared to analysts' expectations of $22.44 billion. During the same period in the previous year, the business posted $2.29 earnings per share. The business's quarterly revenue was up 5.3% compared to the same quarter last year. As a group, analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be paid a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a dividend yield of 3.06%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson's payout ratio is currently 74.59%.

Insider Transactions at Johnson & Johnson

In related news, Director Mark A. Weinberger acquired 1,000 shares of the stock in a transaction dated Thursday, December 12th. The stock was bought at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the transaction, the director now directly owns 1,000 shares of the company's stock, valued at $147,220. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Timothy Schmid sold 403 shares of the company's stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total value of $62,928.45. Following the completion of the sale, the executive vice president now owns 15,098 shares in the company, valued at $2,357,552.70. The trade was a 2.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.16% of the stock is owned by company insiders.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.